Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS)
CNY 62.27
(-1.16%)
CNY 62.27
(-1.16%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 385.41 Million | 302.3 Million | 190.36 Million | 27.66 Million | - | 1.31 Million |
| Cost of Revenue | 29.21 Million | 26.16 Million | 6.26 Million | 27.47 Thousand | 33.26 Million | 893.9 Thousand |
| Gross Profit | 356.2 Million | 276.14 Million | 184.09 Million | 27.63 Million | -33.26 Million | 417.25 Thousand |
| Operating Expenses | 710.45 Million | 779.96 Million | 686.72 Million | 385.66 Million | 440.26 Million | 446.1 Million |
| Selling, General and Administrative Expenses | 251.57 Million | 281.57 Million | 191.34 Million | 78.29 Million | 254.77 Million | 312.6 Million |
| Research and Development Expenses | 458.87 Million | 497.72 Million | 509.39 Million | 314.19 Million | 183.84 Million | 142.8 Million |
| Other Expenses | - | 666.99 Thousand | -14.01 Million | -6.82 Million | 1.65 Million | -10 Thousand |
| Cost and Expenses | 684.22 Million | 806.12 Million | 692.99 Million | 385.69 Million | 440.26 Million | 446.99 Million |
| Operating Income | -408.79 Million | -503.82 Million | -502.63 Million | -358.03 Million | -439.78 Million | -442.64 Million |
| Interest Expense | 24.45 Million | 12.03 Million | 4.41 Million | 1.08 Million | 1.15 Million | 30.61 Thousand |
| Income Tax Expense | -3.94 Million | -2 Million | -3.15 Million | 5.84 Million | 8.19 Million | -780.37 Thousand |
| Earnings before Tax | -299.08 Million | -487.95 Million | -465.14 Million | -304.83 Million | -439.78 Million | -442.65 Million |
| Net Income | -278.58 Million | -485.94 Million | -461.99 Million | -310.67 Million | -447.98 Million | -440.08 Million |
| Earnings Per Share Basic | -1.09 | -2.02 | -1.92 | -1.29 | -1.87 | -2.45 |
| Earnings Per Share Diluted | -1.09 | -2.02 | -1.92 | -1.29 | -1.87 | -2.45 |
| Weighted Average Shares Outstanding | 255.58 Million | 240 Million | 240 Million | 240 Million | 240 Million | 179.71 Million |
| Weighted Average Shares Outstanding (Diluted) | 255.58 Million | 240 Million | 240 Million | 240 Million | 240 Million | 179.71 Million |
| Gross Margin | 0.92 | 0.91 | 0.97 | 1.00 | - | 0.32 |
| EBIT Margin | -0.56 | -1.36 | -2.14 | -9.90 | - | -329.35 |
| Profit Margin | -0.72 | -1.61 | -2.43 | -11.23 | - | -335.65 |
| EBITDA | -214.22 Million | -402.2 Million | -405.55 Million | -256.62 Million | -405 Million | -437.35 Million |
| Earnings Before Tax Margin | -1.06 | -1.67 | -2.64 | -12.94 | - | -337.60 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 143.42 Million | 132.12 Million | 108 Million | 385.41 Million | 104.02 Million | 62.17 Million |
| Cost of Revenue | 9.52 Million | 22.35 Million | 7.14 Million | 83.75 Million | 20.74 Million | 4.95 Million |
| Gross Profit | 133.89 Million | 109.76 Million | 100.85 Million | 301.66 Million | 83.28 Million | 57.21 Million |
| Operating Expenses | 174.44 Million | 159.73 Million | 159.08 Million | 710.45 Million | 221.9 Million | 163.96 Million |
| Selling, General and Administrative Expenses | 166.05 Million | 70.56 Million | 74.74 Million | - | 69.44 Million | 86.41 Million |
| Research and Development Expenses | 91.63 Million | 89.16 Million | 84.34 Million | - | 152.46 Million | 114.87 Million |
| Other Expenses | -83.24 Million | -57.85 Thousand | 442.48 | -1.3 Million | -402.09 Thousand | -318.53 Thousand |
| Cost and Expenses | 183.97 Million | 182.08 Million | 166.23 Million | 794.21 Million | 242.65 Million | 168.92 Million |
| Operating Income | -33.11 Million | -49.96 Million | -58.22 Million | -408.79 Million | -138.62 Million | -94.2 Million |
| Interest Expense | 6.44 Million | 8.33 Million | 7.01 Million | 22.55 Million | 6.24 Million | 6 Million |
| Income Tax Expense | -990.44 Thousand | -972.66 Thousand | -993.04 Thousand | -3.94 Million | -978.04 Thousand | -1.03 Million |
| Earnings before Tax | -33.1 Million | -33.86 Million | -45.62 Million | -299.08 Million | -81.81 Million | -94.52 Million |
| Net Income | -31.36 Million | -27.03 Million | -39.49 Million | -278.58 Million | -76.49 Million | -87.86 Million |
| Earnings Per Share Basic | -0.12 | -0.10 | -0.15 | - | -0.29 | -0.34 |
| Earnings Per Share Diluted | -0.12 | -0.10 | -0.15 | - | -0.29 | -0.34 |
| Weighted Average Shares Outstanding | 264.7 Million | 264.7 Million | 264.7 Million | 255.58 Million | 264.7 Million | 258.41 Million |
| Weighted Average Shares Outstanding (Diluted) | 264.7 Million | 264.7 Million | 264.7 Million | 255.58 Million | 264.7 Million | 258.41 Million |
| Gross Margin | 0.93 | 0.83 | 0.93 | 0.78 | 0.80 | 0.92 |
| EBIT Margin | -0.19 | -0.27 | -0.38 | - | -1.19 | -1.53 |
| Profit Margin | -0.22 | -0.20 | -0.37 | -0.72 | -0.74 | -1.41 |
| EBITDA | -26.66 Million | -35.98 Million | -40.52 Million | - | -124.19 Million | -94.85 Million |
| Earnings Before Tax Margin | -0.23 | -0.38 | -0.54 | -1.06 | -1.33 | -1.52 |
8176
WSPCF
SIGNPOST
FUJIY
C76
NOW